Related Experiment Video
Updated: May 12, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Antiviral therapy for influenza in high-risk outpatients: a multicenter observational study of routine clinical
Ivan Tokin1,2, Dmitry Lioznov3,4, Artem Poromov5,6
1Smorodintsev Research Institute of Influenza, Saint Petersburg 197376, Russian Federation.
Background:
Influenza is a significant public health challenge, characterized by severe disease progression and considerable societal burden. Patients at high risk of influenza-related complications require special attention in routine clinical practice.
Objectives:
This study aimed to compare the effects of antiviral treatments for influenza on the incidence of bacterial complications, adverse events, and disease duration in high-risk outpatients.
Design:
Multicenter, non-interventional, observational cohort study.
Methods:
The study was conducted during the 2023-2024 influenza epidemic season and included 1867 high-risk outpatients treated with oseltamivir, umifenovir, kagocel, or imidazolyl ethanamide pentanedioic acid.
Results:
Bacterial complications occurred in 18.87% (n = 335) of high-risk patients, with 17.41% (n = 309) requiring antibacterial therapy. The hospitalization rate was 1.24% (n = 22), and the average disease duration was 8 days. The incidence of bacterial complications varied among treatment groups: oseltamivir (18.96%, n = 102), umifenovir (12.17%%, n = 51), kagocel (22.00%%, n = 110), and imidazolyl ethanamide pentanedioic acid (22.64%%, n = 72). Adverse events were reported in 4.76% (n = 84) of patients, most commonly gastrointestinal disorders (91.67%, n = 77), followed by allergic reactions (8.33%, n = 7). The incidence of adverse events was significantly higher in the oseltamivir group compared to other treatments.
Conclusion:
The etiotropic agents oseltamivir and umifenovir demonstrated comparable efficacy in managing influenza in high-risk patients, as reflected by their impact on bacterial complication rates and disease duration. Both drugs may be recommended for the treatment of high-risk influenza patients.
More Related Videos
09:07Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Cytomegalovirus Disease
Influenza
Inhibitors of Viral Protein Synthesis